Post-Marketing Non-Acute Safety Study in Japan After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in Persons at High Risk of Severe COVID-19
N/A
The goal of this study is to assess serious adverse events associated with ...
Status
Completed
Location
CMIC Co., Ltd
Start Date
2022-11-15
Trial ID
NCT05894590
COVID Protection After Transplant-Immunosuppression Reduction
PHASE2
This study will enroll individuals who have:
* Completed primary series of...
A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 Vaccines in Healthy Adults Between 18 Years and 55 Years of Age to Prevent COVID-19
PHASE1
The primary goal for this study is to evaluate the safety and reactogenicit...
Status
Completed
Location
Synexus Clinical Research US Phoenix Southeast, Inc.
Study About the Response to the Administration of a Third Dose of mRNA-1273 Vaccine (COVID-19 Vaccine Moderna) in Renal Transplants With Immunological Failure Initial to Vaccination
PHASE2
The objective will be to analyze the development of cellular and humoral im...
Study of a Quadrivalent High-Dose Influenza Vaccine and a Moderna COVID-19 Vaccine Administered Either Concomitantly or Singly in Participants 65 Years of Age and Older Previously Vaccinated With a 2-dose Schedule of Moderna COVID-19 Vaccine
PHASE2
The main purpose of this Phase II study was to assess the safety and immuno...